tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Miller Fisher Syndrome D019846 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Lung Abscess D008169 1 associated lipids
Dysplastic Nevus Syndrome D004416 1 associated lipids
Hypoplastic Left Heart Syndrome D018636 1 associated lipids
Mite Infestations D008924 1 associated lipids
Polyendocrinopathies, Autoimmune D016884 1 associated lipids
Leukoplakia D007971 1 associated lipids
Fasciitis, Necrotizing D019115 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Mathieu C et al. Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7527950
Burke GW et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. 1995 Transplant. Proc. pmid:8539874
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Wennberg L et al. Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:8539967
Yasunami Y et al. Acceptance of donor-specific islet allografts in rat by intraportal preimmunization with islets and FK 506. 1994 Transplant. Proc. pmid:7513467
Murase N et al. Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. 1993 Transplant. Proc. pmid:7679817
Ueki M et al. Functional and morphologic characterization of renal subcapsular islet isografts in rats treated with FK 506. 1994 Transplant. Proc. pmid:7513469
Ito T et al. The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. 1991 Transplant. Proc. pmid:1703716
Morris RE et al. Comparative immunopharmacologic effects of FK 506 and CyA in in vivo models of organ transplantation. 1990 Transplant. Proc. pmid:1689885
Rossi G et al. Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. 1998 Transplant. Proc. pmid:9636562
Wong KM et al. Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study. 2000 Transplant. Proc. pmid:11119907
Yao B et al. The incidence of posttransplantation diabetes mellitus during follow-up in kidney transplant recipients and relationship to Fok1 vitamin D receptor polymorphism. 2013 Jan-Feb Transplant. Proc. pmid:23375298
Miyazaki T et al. Two case reports of successful withdrawal of mycofenolate mofetil after living donor lobar lung transplantation. 2013 Jan-Feb Transplant. Proc. pmid:23375323
Ciancio G et al. Efficacy and safety of daclizumab induction for primary kidney transplant recipients in combination with tacrolimus, mycophenolate mofetil, and steroids as maintenance immunosuppression. 2003 Transplant. Proc. pmid:12644172
Rath T and Küpper M Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715967
Schenker P et al. Modified release tacrolimus in de novo immunosuppression after simultaneous pancreas-kidney transplantation--a first single-center experience. 2009 Jul-Aug Transplant. Proc. pmid:19715977
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients treated with tacrolimus. 2002 Transplant. Proc. pmid:11959335
Garcia VD et al. Corticosteroid reduction with tacrolimus (CORRETA) TRIAL: a prospective Brazilian multicenter, randomized trial of early corticosteroid reduction versus regular corticosteroid dosage maintenance on a tacrolimus (Prograf) and mycophenolate mofetil (Cellcept) immunosuppression regimen in kidney transplant recipients: interim analysis. 2008 Transplant. Proc. pmid:18454988
Todo S et al. Intestinal transplantation in humans under FK 506. 1993 Transplant. Proc. pmid:7680148
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Habucky K et al. The pharmacodynamics of pentobarbital following FK 506 therapy. 1991 Transplant. Proc. pmid:1721282
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Sung RS et al. Survival of human islet xenografts irradiated with ultraviolet B in diabetic rats. 1996 Transplant. Proc. pmid:8623427
Souto-Rodríguez R et al. Differences in the incidence and clinical evolution of early neurotoxicity after liver transplantation based on tacrolimus formulation used in the immunosuppressive induction protocol. 2014 Transplant. Proc. pmid:25420839
Wiebe K et al. FK506 rescue therapy in lung transplantation. 1998 Transplant. Proc. pmid:9636613
Ringe B et al. Replacement of corticosteroids by mycophenolate mofetil in liver graft recipients on initial tacrolimus immunosuppression. 2000 Transplant. Proc. pmid:11120285
Manzia TM et al. Liver transplantation for hepatitis B and C virus-related cirrhosis: mid-term results. 2010 Transplant. Proc. pmid:20534261
Akiyama T et al. Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan. 2005 Transplant. Proc. pmid:15848551
Kahan BD Forty years of publication of transplantation proceedings--the second decade: the cyclosporine revolution. 2009 Transplant. Proc. pmid:19545653
Andrés A et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: single-center experience. 2010 Transplant. Proc. pmid:20970602
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Miyazawa H et al. Mechanisms of hamster kidney graft rejection in the rat. 1994 Transplant. Proc. pmid:7518111
Abouljoud MS et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. 1995 Transplant. Proc. pmid:7533360
Morozumi K et al. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. 1996 Transplant. Proc. pmid:8644331
McCarthy SA et al. Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. 1991 Transplant. Proc. pmid:1721314
Savikko J et al. Tacrolimus inhibits platelet-derived growth factor ligand and receptor induction as well as rejection changes in rat renal allografts during long-term follow-up. 2002 Transplant. Proc. pmid:12176405
Akioka K et al. Abdominal pain is a critical complication of mycophenolate mofetil in renal transplant recipients. 2003 Transplant. Proc. pmid:12591411
Kitamura T et al. Severe hemolytic anemia related to production of cold agglutinins following living donor liver transplantation: a case report. 2003 Transplant. Proc. pmid:12591458
Hohage H et al. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. 2005 Transplant. Proc. pmid:15919453
Sakai K et al. The pathologic impact of tacrolimus on protocol biopsy in renal transplant patients with basiliximab-based immunosuppression. 2005 Transplant. Proc. pmid:15919455
Zhang XJ et al. Effects and mechanisms of tacrolimus on development of murine Th17 cells. 2010 Transplant. Proc. pmid:21094856
Masri MA Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. 1995 Transplant. Proc. pmid:7533412
Jiang H et al. Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine. 1995 Transplant. Proc. pmid:7533413
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Nakamura K et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. 1991 Transplant. Proc. pmid:1721346
Borda B et al. Early histopathological changes in new-onset diabetes after kidney transplantation. Transplant. Proc. pmid:25131129
Porubsky M et al. Excellent outcomes can be achieved in young pancreas transplant alone recipients by addition of sirolimus to maintenance immunosuppression regimen. Transplant. Proc. pmid:25131074
Prates LC et al. Pain syndrome induced by calcineurin inhibitor and resolved by conversion to sirolimus in a child after kidney transplantation: a case report. 2012 Transplant. Proc. pmid:23026634
Solà R et al. Tacrolimus in induction immunosuppressive treatment in renal transplantation: comparison with cyclosporine. 2003 Transplant. Proc. pmid:12962763
Nishi K et al. The colon displays an absorptive capacity of tacrolimus. 2004 Transplant. Proc. pmid:15050160
Bardella MT et al. FK 506 and cyclosporine: effect on D-xylose absorption in pigs with orthotopic liver-small bowel allotransplants. 1996 Transplant. Proc. pmid:8907937
Ciancio G et al. Effect of daclizumab, tacrolimus and mycophenolate mofetil in racial minority first renal transplant recipients. 2002 Transplant. Proc. pmid:12176508
Gringeri E et al. Neoadjuvant therapy protocol and liver transplantation in combination with pancreatoduodenectomy for the treatment of hilar cholangiocarcinoma occurring in a case of primary sclerosing cholangitis: case report with a more than 8-year disease-free survival. 2011 Transplant. Proc. pmid:21620084
Ota K Living donor kidney transplantation in Japan. 1994 Transplant. Proc. pmid:7520622
Perico N et al. FK 506 does not affect the glomerular filtration rate and renal plasma flow in the rat. 1991 Transplant. Proc. pmid:1721378
Mieles L et al. Glycemia and insulin need following FK 506 rescue therapy in liver transplant recipients. 1991 Transplant. Proc. pmid:1703362
Rastellini C et al. Prolonged survival of islet allografts following combined therapy with tacrolimus and leflunomide. 1999 Feb-Mar Transplant. Proc. pmid:10083278
Rao AS et al. Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions. 1999 Feb-Mar Transplant. Proc. pmid:10083302
Jambaljav L et al. Kidney transplantation achievements in Mongolia. 2010 Transplant. Proc. pmid:20430173
Millis JM et al. Tacrolimus treatment of steroid-resistant rejection provides economic advantages compared with OKT3 therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123421
Corry RJ et al. Pancreas transplantation with enteric drainage under tacrolimus induction therapy. 1997 Feb-Mar Transplant. Proc. pmid:9123457
Mollison KW et al. Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat. 1996 Transplant. Proc. pmid:8962236
McGrath JS and Shehata M The effect of differing immunosuppressive regimes on the functional and morphologic changes in a rat renal allograft model of chronic rejection. 2001 Transplant. Proc. pmid:11377499
Yokoyama I et al. Decreased Fas antigen expression of cultured hepatocytes with FK 506. 1996 Transplant. Proc. pmid:8962237
Koefoed-Nielsen PB and Jørgensen KA Alterations in calcineurin phosphatase activity in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176559
Tsai SF et al. Trends in maintenance immunosuppressive drugs used in taiwanese kidney transplant recipients: an analysis of the national health insurance research database. 2012 Transplant. Proc. pmid:22310612
Tai J et al. In vivo and in vitro effect of FK 506 on rat Leydig cell function. 1991 Transplant. Proc. pmid:1721409
Sato Y et al. FK 506 suppresses class II antigen expression in regenerating livers following partial hepatectomy in the rat. 1992 Transplant. Proc. pmid:1379761
Pretagostini R et al. Conversion from cyclosporin to tacrolimus in chronic allograft nephropathy. 2001 Feb-Mar Transplant. Proc. pmid:11267174
Dresske B et al. Synergistic impact of "WOFIE" on the immunosuppressive potency of FK 506 in a heterotopic heart transplantation model in the rat. 1999 Transplant. Proc. pmid:10331001
Sicilia-Castro D et al. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: a case report. 2011 Transplant. Proc. pmid:21911174
Dedhia P et al. Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report. Transplant. Proc. pmid:28104134
Kanatani T et al. Donor leukocytes combine with immunosuppressive drug therapy to prolong limb allograft survival. 2005 Transplant. Proc. pmid:15964421
Gnatta D et al. Use of tacrolimus and the development of posttransplant diabetes mellitus: a Brazilian single-center, observational study. 2010 Transplant. Proc. pmid:20304169
Behr TM et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. 1998 Transplant. Proc. pmid:9723333
Wiederkehr JC et al. Prevalence of posttransplantation lymphoproliferative disease in pediatric liver transplant recipients. 2010 Transplant. Proc. pmid:20304183
Trotter JF Sirolimus in liver transplantation. 2003 Transplant. Proc. pmid:12742496
MacDonald AS Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. 2003 Transplant. Proc. pmid:12742497
Ventura E et al. Calcineurin Inhibitor Determination in Whole Blood With the RXL Dimension Analyzer: A Useful Tool for Immunosuppressive Drug Monitoring. 2009 Transplant. Proc. pmid:19328963
Ziedina I et al. Reactivation of BK Virus in the Early Period After Kidney Transplantation. 2009 Transplant. Proc. pmid:19328975
Ojogho ON et al. Mycophenolate mofetil without antibody induction in pediatric renal transplantation. 2002 Transplant. Proc. pmid:12176641
van der Laan LJ et al. Results of a two-center study comparing hepatic fibrosis progression in HCV-positive liver transplant patients receiving cyclosporine or tacrolimus. 2010 Transplant. Proc. pmid:21168740
Sindhi R et al. Pharmacodynamics of sirolimus in transplanted children receiving tacrolimus. 2002 Transplant. Proc. pmid:12176644
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Katayama Y et al. Immunosuppressive effects of FK 506 in rat lung transplantation. 1991 Transplant. Proc. pmid:1721441
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Ochiai T et al. Effects of FK-506 on xenotransplantation of the heart and skin in a mouse-rat combination. 1987 Transplant. Proc. pmid:2445083
Odocha O et al. Serum cholesterol levels in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689269
Nalesnik MA et al. Toxicology of FK-506 in the Lewis rat. 1987 Transplant. Proc. pmid:2445084
Heffron TG et al. Single-dose induction with daclizumab immediately after liver transplantation in pediatric patients. 2001 Feb-Mar Transplant. Proc. pmid:11267368
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Baraldo M Meltdose Tacrolimus Pharmacokinetics. 2016 Transplant. Proc. pmid:27109969
Bárcena R et al. Immunosuppression in liver transplantation: a European survey. 1999 Transplant. Proc. pmid:10500654
Nicholson ML et al. Is TGF-beta a profibrotic cytokine in human renal transplants? 1998 Transplant. Proc. pmid:9636384
Garcia CD et al. Pediatric renal transplantation under tacrolimus or cyclosporine immunosuppression and basiliximab induction. 2002 Transplant. Proc. pmid:12431513
Lautenschlager I et al. Efficiency of FK 506 and CyA to prevent acute cellular rejection of pig liver allografts. 1991 Transplant. Proc. pmid:1714650
Eghtesad B et al. Use of tacrolimus as the primary immunosuppression after renal transplant in Native Americans and Hispanics. 1998 Transplant. Proc. pmid:9636500
Turner CD et al. Tacrolimus therapy for refractory acute renal allograft rejection: a 4-year experience with an aggressive approach. 1998 Transplant. Proc. pmid:9636501
Pichlmayr R et al. Three-year follow-up of the European Multicenter Tacrolimus (FK506) Liver Study. 1997 Transplant. Proc. pmid:9270825